At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
APRE Aprea Therapeutics, Inc.
Market Closed 12-27 16:00:00 EST
3.37
+0.00
0.00%
盘后3.45
+0.08+2.37%
19:42 EST
High3.70
Low3.32
Vol24.66K
Open3.32
D1 Closing3.37
Amplitude11.28%
Mkt Cap18.32M
Tradable Cap13.41M
Total Shares5.43M
T/O85.54K
T/O Rate0.62%
Tradable Shares3.98M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
BRIEF-Aprea Therapeutics Announces Twice Daily (Bid) Dosing Of Patients In ABOYA-119 Clinical Trial Of ATRN-119 To Potentially Optimize Clinical Outcomes
Aprea Therapeutics Announces Twice Daily (Bid) Dosing of Patients in Aboya-119 Clinical Trial of Atrn-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward
BRIEF-Aprea Therapeutics - Got Into At The Market Offering Agreement, May Offer & Sell Shares Of Common Stock Of Up To $3 Million From Time To Time - SEC Filing
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.